The Week

Sutro Biopharma (STRO) added 2.73% this week to close at $21.04, while the S&P 500 slipped 1.43% — a relative outperformance of roughly 4.16 percentage points. The week played out as a sharp rally followed by a pullback. Monday (17 Aug) saw the stock jump from $20.54 to $22.28, and the momentum carried into Tuesday with an intraday high of $22.99. Wednesday’s session marked the week’s peak at $23.45 before the tide turned. Thursday and Friday brought two straight sessions of profit-taking, with the stock settling at $21.04 on the final day. The week’s high-low spread of 15.77% points to unusually wide swings. No company-specific news hit the tape during the period, leaving the price action largely at the mercy of broader market sentiment.

Analyst Ratings

Fourteen brokers cover Sutro Biopharma: 10 rate it buy, 3 rate it overweight, and 1 rates it underweight — no hold or sell ratings on the board. The consensus rating is ‘strong buy’, with a consensus target of $47.23, implying roughly 124.48% upside from the latest close. The target range, however, is strikingly wide — from a low of $10 to a high of $61 — signalling a deep split in conviction among analysts. Within the biotech sector, the stock sits at rank 76 out of 505 peers, placing it in the upper-middle tier of the coverage universe.

The Week Ahead

No company-specific events are on the calendar for Sutro Biopharma next week. The main focus shifts to the macro front, with Tuesday (25 Aug) bringing a wave of US data: FHFA house prices, the Case Shiller 20-city index, the Richmond Fed composite index, consumer confidence (prior 90.8, forecast 90.1), and new home sales (prior 628k, forecast 620k). The housing and sentiment readings could sway risk appetite across the biotech space, and small- to mid-cap growth names like STRO may feel the knock-on effect of any shift in the macro mood.

This article is generated by LongbridgeAI from market data, for information only and not investment advice.